

Cinnamomum osmophloeum and Oral Mucositis

Subjects: Biology

Contributor: SHIH-CHIEH LEE

Cinnamon plants (*Cinnamomum* spp.) are of the genus Lauraceae, native to South and Southeast Asia, and are generally used as food flavors and traditional medicinal plants. *Cinnamomum osmophloeum*, commonly known as indigenous cinnamon or pseudocinnamon, is endemic to Taiwan's natural hardwood forests.

Keywords: *C. osmophloeum* ; biological activities ; oral mucositis ; cinnamaldehyde ; linalool

1. Introduction

Cinnamon plants (*Cinnamomum* spp.) are of the genus Lauraceae, native to South and Southeast Asia, and are generally used as food flavors and traditional medicinal plants. *Cinnamomum osmophloeum*, commonly known as indigenous cinnamon or pseudocinnamon, is endemic to Taiwan's natural hardwood forests ^[1]. Major components of the essential oils extracted from *C. osmophloeum* leaves explored by high-performance liquid chromatography (HPLC) are as follows: α -pinene, camphene, benzaldehyde, β -pinene, 3-phenyl pionaldehyde, *cis*-cinnamaldehyde, *trans*-cinnamaldehyde, isobornylacetate, eugenol, and cinnamyl acetate ^[2]. The essential oils extracted from *C. osmophloeum* leaves comprise 101 volatile compounds, as identified by GC/MS analysis, including monoterpenoids, sesquiterpenoids, alcohols, phenols, aldehydes, ketones, esters, acids, and other miscellaneous compounds. It was demonstrated that the linalool chemotypes present in *C. osmophloeum* were as follows: linalool, *trans*-cinnamyl acetate, camphor, cinnamaldehyde, 3-phenyl-2-propenal, caryophyllene, coumarin, bornyl acetate, limonene, α -(+)-pinene, estragole, and caryophyllene oxide ^[3]. In several studies (both *in vitro* and *in vivo*), *C. osmophloeum* has been applied as an alternative natural therapy to treat certain compromised and uncompromised diseases ^{[3][4][5][6][7]}.

Oral mucositis (OM) is known as the inflammation of oral mucosa, usually occurring as an adverse side-effect of chemotherapy and/or radiation therapy (radiotherapy), and is manifested as atrophy, swelling, erythema, and ulceration ^[8]. OM occurrence in the hospital might increase costs and deteriorate oral health quality of life ^{[9][10][11]}. Hence, oral care treatments, including nutritional care, pain control, oral cleansing, palliation of a dry mouth, bleeding handling, and medicinal interventions have been introduced to decrease the severity of OM after cancer therapy ^[12]. Patients receiving radiotherapy to head and neck areas are at a significant risk of developing oral mucositis. The risk is lower (less than 50% or little risk) in patients with prolonged chemotherapy, patients receiving surgery, and patients with radiotherapy to non-head and neck areas ^{[10][13]}. The underlying pathophysiology of OM is divided into five phases: (1) initiation, (2) primary damage response, (3) signaling and amplification, (4) ulceration (symptomatic phase), and (5) healing ^{[14][15][16]}. The first phase (initiation stage) happens after exposure to radiotherapy or chemotherapy. It consists of two events: DNA breakdown and the generation of reactive oxygen species (ROS). DNA strand breakdowns lead to direct injury and death of the cells, and reactive oxygen species play a role as key initiators and mediators of downstream biological events. During the second phase (primary damage response), activator transduction pathways are stimulated by the DNA breaks strand, which can lead to the activation of several transcription factors, including p53 and nuclear factor kappa-B (NF- κ B). NF- κ B works as a controller for the expression of a broad range of genes, and produces a series of mediators, including pro-inflammatory cytokines and both pro- and anti-apoptotic cellular changes. During phase III (signal amplification stage), pro-inflammatory cytokines deliver a positive reaction to enhance and accelerate the process of wound healing. During phase IV (ulceration phase, also called symptomatic phase), it is common for the mucosal surface to become re-infected with bacteria. Bacterial invasion stimulates macrophage accumulation to conceal additional amounts of pro-inflammatory cytokines. During phase V (healing stage), signals from the connective tissue to the bordering epithelium can activate the migration, propagation, and differentiation of cells, resulting in healed mucosa. A number of biomaterials explored for OM therapy perform their principal mechanisms linked to pathophysiology by depressing pro-inflammatory cytokines. In addition to anti-inflammation, antioxidant, antifungal, antibacterial, and immunomodulator mechanisms of action have been reported ^[17]. As one of the encouraging biomaterials, *C. osmophloeum* might be a potential alleviator of OM.

2. Medical-Biological Activities of *C. osmophloeum*

Table 1. Beneficial biological activities of *C. osmophloeum*.

Bioactivity	Chemical Identification	<i>C. osmophloeum</i> Parts	Constituent (s)	Study	Mechanisms	Reference
Anti-inflammatory effect	LC-MS/MS	Leaves	Kaempferitrin	In vitro	Down-regulate the extracellular LDL-R (chronic inflammation-related diabetes mellitus)	Ku et al., (2017) ^[18]
	GC-MS	Twigs	Trans-cinnamaldehyde, caryophyllene oxide, L-borneol, L-bornyl acetate, eugenol, β -caryophyllene, E-nerolidol, and cinnamyl	In vitro	Suppressing nitric oxide synthesis by LPS-stimulated macrophages	Tung et al. (2008) ^[19]
	GC-MS	Leaves	Trans-cinnamaldehyde, (-)-aromadendrene, caryophyllene oxide, T-cadinol, and α -cadinol	In vitro	Suppressing nitric oxide production by LPS-stimulated macrophages	Tung et al. (2010) ^[20]
	GC-MS and HPLC	Leaves	Cinnamaldehyde	In vitro	Cinnamaldehyde inhibits LPS-mediated pro-inflammatory cytokine production	Chao et al. (2008) ^[21]
	TLC	Leaves	NA	In vitro	Inhibition of the production of NO and cytokines (TNF- α and IL-12), from LPS/IFN γ -activated macrophages	Fang, Rao & Tzeng (2005) ^[22]
	CC, HPLC, TLC, ESIMS, and GC-MS	Twigs	Kaempferol glycosides	In vitro	Nitric oxide production inhibitory activities	Lin & Chang(2012) ^[23]
	GC-MS	Leaves	Linalool and cinnamaldehyde	In vivo	Inhibition of the expression of molecules in both TLR4 and NLRP3 signaling pathways	Lee et al. (2018) ^[24]
	GC-MS	Leaves	21 compounds were identified	In vitro	Inhibition of IL-1 α and IL-6 production	Chao et al. (2005) ^[25]
Antibacterial activity	GC	Leaves	Cinnamaldehyde	In vitro	Bactericidal	Chang, Chen & Chang (2001) ^[26]
	GC-MS	Leaves	Cinnamaldehyde, cinnamic acid, cinnamyl alcohol, and cinnamyl acetate	In vitro	Bacterial inhibition	Chang et al. (2008) ^[27]
Antifungal activity	GC-MS	Leaves	Cinnamaldehyde	In vitro	NA	Cheng et al. (2006) ^[28]
	GC-MS	Leaves	Cinnamaldehyde	In vitro	NA	Wang, Chen & Chang (2005) ^[29]

Bioactivity	Chemical Identification	<i>C. osmophloeum</i> Parts	Constituent (s)	Study	Mechanisms	Reference
Antioxidant activities	ESIMS	Twigs	Kaempferol-7-O-rhamnoside	In vitro	NA	Chua, Tung, & Chang (2008) ^[30]
	GC-MS and GC-FID	Leaves	Alloaromadendrene	In vitro	NA	Yu et al. (2014) ^[31]
	GC-MS and GC-FID	Leaves	Trans-cinnamaldehyde	In vitro	NA	Yeh et al. (2013) ^[32]
	GC-MS and GC-FID	Leaves	Trans cinnamaldehyde	In vivo	Expression of antioxidative-related genes was pointedly affected by essential oils from <i>C. osmophloeum</i> .	Hsu et al. (2012) ^[33]
Antidyslipidemic activity	HPLC	Leaves	Kaempferol and kaempferitrin	In vivo	Cholesterol-lowering activity	Lin et al. (2011) ^[34]
Anti-hyperglycemic and antioxidant activities	A modified vanillin-H ₂ SO ₄ assay A modified acid-butanol assay The AlCl ₃ method	Twigs	Proanthocyanidin and tannin contents	In vitro	CoTE has PTP1B inhibitory activity to improve insulin or leptin resistance	Lin et al. (2016) ^[35]
Hepatoprotective effects	NA	Leaves	trans-cinnamaldehyde, ()-aromadendrene, T-cadinol, or R-cadinol	In vivo	The modulation of anti-inflammatory activities (decreased the aspartate aminotransferase (AST), alanine aminotransferase (ALT), tumor necrosis factor-R (TNF-R), and interleukin 6 (IL-6) levels in serum)	Tung et al. (2011) ^[6]
Pancreas Protective Effect and Hypoglycemic activity	GC/MS	Leaves	Linalool	In vivo	1. Decreased pancreatic values of thiobarbituric acid reactive substances and activities of superoxide dismutase and glutathione reductase 2. Decreased pancreatic levels of interleukin-1 β and nitric oxide	Lee et al. (2013) ^[3]
Prevent Cardiac Hypertrophy	HPLC	Leaves	Cinnamaldehyde	In vivo	The protective role of cinnamaldehyde related to the ERK1/2 signaling pathway.	Yang et al. (2015) ^[7]
Treatment of renal interstitial fibroblasts	NA	Leaves	Cinnamaldehyde	In vitro	Inhibit high glucose-induced hypertrophy (decreased cell size; cellular hypertrophy index; and protein levels of collagen IV, fibronectin, and α -smooth muscle actin).	Chao et al. (2010) ^[4]

Bioactivity	Chemical Identification	C. <i>osmophloeum</i> Parts	Constituent (s)	Study	Mechanisms	Reference
Anticancer (liver and oral cancer)	TLC, CC and HPLC	Heart wood and roots	Lignan Esters	In vitro	Tumor cell growth inhibition	Chen et al. (2010) ^[36]
Anti-diabetes	TLC	Twigs	Kaempferol glycosides CO-1 and CO-2	In vitro	Enhanced adiponectin secretion, and activation of the insulin signaling pathway	Lee et al. (2009) ^[37]
Anti-hyperuricemia effect	GC-MS	Leaves	Cinnamaldehyde	In vivo	Acts as a xanthine oxidase inhibitor and reduces the serum uric acid levels	Wang et al. (2008) ^[2]
Anxiolytic properties	HPLC	Leaves	Linalool	In vivo	Reduced the amount of 5-HT, DA and NE and increased the level of dopamine in striatum	Cheng et al. (2014) ^[38]
Wound Repair Promoter and Antioxidant	NA	Leaves	NA	In vitro and in vivo	Inhibited tyrosinase activity and reduced melanin content	Lee et al. (2015) ^[39]
Anti-inflammatory and anti-cancer properties	NA	Barks	NA	In vivo	The growth inhibition of NO, TNF-, and IL-12, and tumor cell proliferation	Rao et al. (2007) ^[40]
Hypolipidemic effects	NA	Leaves	S-(p)-linalool	In vivo	Inhibited lipid accumulation through downregulation of 3T3-L1 adipocyte differentiation	Cheng et al. (2018) ^[41]
Effect on the human immune system	HS-GC/MS and HPLC	Leaves	Cinnamaldehyde	In vivo	Cytokines modulatory effect	Lin et al. (2011) ^[42]
Potential skin-whitening and protective agent	NA	Leaves	Cinnamaldehyde and cinnamylacetate	In vitro	Neutralized the IBMX-induced increase in melanin content in B16-F10 cells by inhibiting tyrosinase gene expression at the level of transcription	Lee et al. (2015) ^[39]
Anti-inflammatory effect in intestine	GC/MS	Leaves	Linalool	In vivo	The suppression of the TLR4 pathway by CO and partly by the inhibitory effect of CO on the activity of xanthine oxidase	Lee et al. (2015) ^[43]
Anti-tumor	NA	Leaves	Trans-cinnamaldehyde	In vitro	Trans-cinnamaldehyde triggers suicidal death of erythrocytes, i.e., cells devoid of mitochondria and gene expression.	Theurer et al. (2013) ^[44]

Bioactivity	Chemical Identification	<i>C. osmophloeum</i> Parts	Constituent (s)	Study	Mechanisms	Reference
Dietary supplements and treatment of hyperuricemia and gout	GC-MS and GC-FID	Leaves	Cinnamaldehyde	In vitro	The xanthine oxidase inhibitory activity	Huang et al. (2018) ^[45]
Anti-hyperglycemic and antioxidant activities	(MALDI/MS) (RP-HPLC) /MS/MS	Twigs	Proanthocyanidin	In vitro	The proanthocyanidins in CoTE mainly consisted of (epi)catechin and contained at least one A-type linkage. The inhibitory activity of α -glucosidase and α -amylase	Lin et al. (2016) ^[46]

NA: Not available; LC: liquid chromatography; MS: mass spectrometry; GC: gas chromatography; HPLC: high-performance liquid chromatography; TLC: thin layer chromatography; CC: column chromatography; ESIMS: electrospray ionization mass spectrometry; GC-FID: gas chromatography–flame ionization detection; MALDI: matrix-assisted laser desorption/ionization; RP: reverse phase.

3. Potential Use of *C. osmophloeum* for the Treatment of Oral Mucositis (OM)

The current protocols of medicine for chemotherapy are associated with oral mucositis. Cytarabine, high-dose 5-fluorouracil, alkylating agents, and platinum-based compounds are highly associated with the incidence of oral mucositis. Actinomycin D, amsacrin, bleomycin, busulfan, capecitabine, carboplatin, chlorambucil, cisplatin, cytarabine, docetaxel, doxorubicin, etoposide, floxuridine, ifosfamide, irinotecan, leucovorin, methotrexate, mitoxantron, oxaliplatin, paclitaxel, plicamycin, tioguanin, vinblastine, vincristine, vindesine, and vinorelbine (the protocol can be combined) are the medicines used for chemotherapy and are reported to lead to the development of oral mucositis ^{[47][48]}. In order to prevent oral mucositis, the Multinational Association of Supportive Care in Cancer (MASCC) and International Society of Oral Oncology (ISOO) help clinics by comprising Clinical Practice Guidelines for Oral Mucositis ^[49]. The recommendations are comprised of basic oral care, growth factors and cytokines, anti-inflammatory agents, laser and other light therapy, cryotherapy, and natural and miscellaneous agents (Table 2). Köstler et al. provided several experimental approaches to treat oral mucositis; they included locally applied non-pharmacological methods, anti-inflammatory and mucosa protectant agents, cytokines, granulocyte colony-stimulating factor (G-CSF, filgrastim) and granulocyte-macrophage colony-stimulating factor (GM-CSF, molgramostim), antiseptic agents, corticosteroids, mouth-coating agents, and dexampanthenol ^[48].

Table 2. Interventions to prevent oral mucositis (clinical practice guidelines) proposed by the Multinational Association of Supportive Care in Cancer (MASCC) and International Society of Oral Oncology (ISOO).

Intervention	Protocol	Population	Evidence of Effectiveness
Basic oral care	Tooth brushing, flossing, and one mouth rinse	All age groups and across all cancer treatment modalities	Not strong evidence
Growth factors and cytokines	Palifermin (keratinocyte growth factor-1)	Patients receiving high-dose chemotherapy and total body irradiation, followed by autologous stem cell transplantation for hematological malignancies	Strong evidence
Anti-inflammatory agents	Benzylamine mouthwash	Patients with head and neck cancer receiving moderate-dose radiation therapy (up to 50 Grays), without concomitant chemotherapy	Strong evidence
Laser and other light therapy	Low-level laser therapy (LLLT)	Patients receiving high-dose chemotherapy for HSCT with or without total body irradiation	Strong evidence
Cryotherapy	The placement of ice chips in the mouth	Patients receiving bolus dosing of 5-fluorouracil	Strong evidence

Intervention	Protocol	Population	Evidence of Effectiveness
Natural and miscellaneous agents	Systemic zinc supplements administered orally (antioxidant effect)	Patients with oral cancer undergoing radiotherapy or chemoradiation	Not strong evidence

The study of *C. osmophloeum* and/or its constituents in OM are limited. In one study, the effect of cinnamaldehyde on oral mucositis and an evaluation of the salivary total antioxidant capacity of gamma-irradiated rats were carried out. The saliva samples were taken from the rats in triplicate [50]. In order to evaluate the consequences and severity of mucositis, the conditions of the oral cavity were assessed by using Parkin's clinical scale, where 0 represents normal mucosa, 0.5 indicates normally pink mucosa, 1 stands for minor red mucosa, 2 is severe red mucosa, 3 is local desquamation, 4 describes exudation and crust around less than half of the lip area, and 5 characterizes exudation and crust for more than half of the lip area [51]. The authors concluded that the clinical effects in the intervention group seemed to be due to the antioxidant, antibacterial, and anti-inflammatory effects of cinnamaldehyde. It is noteworthy to mention that through anti-inflammation and antioxidant mechanisms, cinnamaldehyde would delay the onset of oral mucositis. Moreover, alteration in the oral microflora of existing bacteria in the fourth phase (ulceration phase) could exacerbate the severity of mucositis, whereas cinnamaldehyde alleviated oral mucositis via its antibacterial properties [50]. A recent investigation reported the effect of cinnamon bark fractions (an essential oil and an aqueous extract) on *Candida albicans* growth inhibition (growth, biofilm formation, and adherence properties) and oral epithelial cells (barrier integrity and inflammatory response) [52]. The anti-adherence and anti-inflammatory properties of proanthocyanidins, a family of polyphenols containing flavan-3-ol oligomers and polymers, are used to treat oral infections [52][53]. The two pro-inflammatory cytokines, IL-6 and IL-8, which serve as important cytokines in the development of oral mucositis, were reduced by an aqueous extract enriched with proanthocyanidins of the cinnamon fraction. This shows that the cinnamon presented in the study may be a promising agent in the alleviation of oral mucositis [52].

Other biomaterials or herbal products, such as *Aloe vera*, *Acacia catechu*, Chamomile, Hangeshashinto, indigowood root (*Isatis indigotica* Fort.), honey, *Traumeel S*, water grass decoction, and *Weleda Ratanhia*, also showed similar effects on the alleviation of OM via anti-inflammation activities [17][54][55][56][57][58][59][60][61][62][63]. The bioactive properties of the yarrow plant (*Achillea millefolium*), honey, *Callendula officinalis* flowers, *Hipophae rhamnoides* L. plant, Chamomile, and *Aloe vera* were associated with antioxidant, anti-inflammatory, antibacterial, and wound healing effects of oral mucositis therapy (Table 3) [55][56][57][63][64][65][66][67][68]. Similar to the advantages of the medical-biological activities of these herbal agents, *C. osmophloeum* would provide an identical mechanism for relieving oral mucositis.

Table 3. Bioactive properties of natural agents for oral mucositis therapy.

Natural Agents	Bioactivity	References
Yarrow Plant (<i>Achillea millefolium</i>)	Anti-bacterial and anti-inflammatory effect	Mirazandeh et al. (2014) [64]
Manuka Honey (<i>Leptospermum scoparium</i>)	Wound healing and anti-microbial	Hawley et al. (2013) [63]
Weleda Pflanzen-Zahngel and Weleda Ratanhia-Mundwasser	Anti-inflammatory, anti-bacterial, and lesion healing	Tiemann et al. (2007) [61]
<i>Calendula officinalis</i> flowers	Anti-inflammatory, anti-bacterial, and anti-oxidant	Babae et al. (2013) [65]
Honey and coffee	Antioxidant, anti-microbial, and anti-inflammatory	Raeessi et al. (2014) [54]
<i>Aloe vera</i>	Anti-inflammatory, bactericidal, and wound healing	Sahebamee et al. (2015) [62]
Hangeshashinto: <i>Pinelliae tuber</i> , <i>Scutellariae Radix</i> , <i>Glycyrrhizae Radix</i> , <i>Zizyphi Fructus</i> , <i>Ginseng Radix</i> , <i>Zingiberis Processum rhizoma</i> , and <i>Coptidis rhizome</i>	Anti-inflammatory	Aoyama et al. (2014) [58]
Indigowood Root (<i>Isatis indigotica</i> Fort.)	Anti-inflammatory	You et al. (2009) [60]
Topical Honey	Anti-inflammatory, anti-microbial, and wound healing	Khanal et al. (2010) [66]

Natural Agents	Bioactivity	References
<i>Hippophae rhamnoides</i> L. plant	Anti-oxidant, anti-ulcerogenic, anti-inflammatory, anti-microbial, and proinflammatory cytokine Antagonist	Kuduban et al. (2016) ^[67]
Honey from the clover plant <i>Trifolium alexandrenum</i>	Anti-microbial	Rashad et al. (2009) ^[69]
Qingre Liyan decoction	Anti-oxidant and anti-inflammatory	Lambros et al. (2014) ^[70]
Hangeshashinto	Anti-inflammatory and anti-microbial	Kono et al. (2014) ^[56]
Chamomile	Anti-inflammatory, anti-bacterial, and antifungal	Fidler et al. (1996) ^[55]
<i>Rhodila algida</i>	Anti-oxidant and immunostimulant	Loo et al. (2010) ^[71]
Qingre Liyan Decoction	Enhancing body immunity and promoting salivary EGF	Wu et al. (2007) ^[72]
Chamomile	Anti-inflammatory, anti-bacterial, and anti-fungal	Pourdeghatkar et al. (2017) ^[57]
Pure Honey	Anti-bacterial and anti-inflammatory	Motallebnejad et al. (2008) ^[68]
<i>Aloe vera</i>	Anti-inflammatory, anti-bacterial, and anti-fungal	Puataweepong et al. (2009) ^[73]
<i>Aloe vera</i> and vitamin E	Antioxidant, anti-inflammatory, and healing properties	Cuba et al. (2015) ^[74]
Traumeel S	Anti-inflammatory	Sencer et al. (2012) ^[75]
<i>Chamomilla recutita</i>	Anti-inflammatory	Braga et al. (2015) ^[76]
Wild chamomile (<i>Matricaria recutita</i> L.)	Anti-inflammatory, anti-bacterial, and anti-fungal	Mazokopakis et al. (2003) ^[56]

According to antibacterial mechanisms, several studies demonstrated bacterial changes due to radiotherapy and/or chemotherapy ^[76]. The bacteria were *Gemella haemolysans*, *Streptococcus mitis* ^[77], *Escherichia coli*, *Pseudomonas aeruginosa*, *Enterobacter* sp., *Klebsiella pneumonia* ^[78], *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Parvimonas micra*, *Fusobacterium nucleatum*, *Treponema denticola*, *C. glabrata*, *C. kefyr* ^[79], and *Porphyromonas gingivalis* ^[80]. Among these bacteria, *C. osmophloeum* has been confirmed to possess the antibacterial properties of *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Staphylococcus epidermidis* (Figure 1) ^[26].




Figure 1. Antibacterial properties of *C. osmophloeum* (A) and bacterial infection of oral mucositis (B).

Flavonoid-rich fractions containing kaempferitin in *Bauhinia forficata* leaves have been investigated and shown to be effective ingredients for preventing the intestinal toxic effects of irinotecan chemotherapy. It was stated that kaempferitin, as one of the major active contents of *C. osmophloeum*, has been tested to prevent or reduce the severity of intestinal mucositis [18][81]. The chemotherapy drug 5-Fluororacil possesses side effects (i.e., induces mucositis manifestations in oral and gastrointestinal after chemotherapy). *Chimonatus Nitens* var. *salicifolius* aqueous extract contains three flavonoid contents: quercetin, kaempferol, and rutin, which might have an anti-inflammatory effect on gastrointestinal mucositis [82]. Kaempferol, cinamic acid, and nine other constituents obtained in mucoadhesive propolis agent have been proven to be effective in reducing radiation-induced oral mucositis. A clinical study of 24 patients revealed that mucositis only developed in two patients and each developed grade 1 mucositis and grade 2 mucositis, respectively; however, in the remaining 20 patients, mucositis did not develop [83].

Previous studies investigated the potential of *C. osmophloeum* to reduce oral mucositis. Nonetheless, *C. osmophloeum*, which is a species of cinnamon, faces challenges in its use as an oral treatment. In addition, this review has several limitations. First, there are limited data on the medical-biological effects of *C. osmophloeum* and its potential use in oral mucositis therapy. Secondly, the reported events related to oral stomatitis allergy induced by cinnamon should be a concern [84][85][86]. In summary, *C. osmophloeum* and its constituent are anticipated to be effective and efficient in reducing the severity of OM by preventing secondary bacterial infection through their bactericidal activity, preventing the development of the second phase of OM (the primary damage response) or interrupting the third phase in which pro-inflammatory cytokines could enhance and accelerate the process of wound healing (Figure 2).




Figure 2. Proposed potential use of *C. osmophloeum* in the alleviation of oral mucositis (OM). *C. osmophloeum* ameliorated oxidative stress and pro-inflammation through its constituents. Several studies have investigated the anti-inflammation, antibacterial, and antioxidant activities. The review of medical-biological activities showed that *C. osmophloeum* and its constituents inhibit the pro-inflammatory response. *C. osmophloeum* potentially prevents the second phase of oral mucositis (the primary damage response) or may intercept in the third phase, with pro-inflammatory cytokines providing a positive reaction to enhance and accelerate the process of wound healing. *C. osmophloeum* was also confirmed to be bactericidal and inhibit bacteria which can reduce the severity of oral mucositis or secondary bacterial infection.

References

1. Ribeiro-Santos, R.; Andrade, M.; Madella, D.; Martinazzo, A.P.; de Aquino Garcia Moura, L.; de Melo, N.R.; Sanches-Silva, A. Revisiting an ancient spice with medicinal purposes: Cinnamon. *Trends Food Sci. Technol.* 2017, 62, 154–169.
2. Wang, S.Y.; Yang, C.W.; Liao, J.W.; Zhen, W.W.; Chu, F.H.; Chang, S.T. Essential oil from leaves of *Cinnamomum osmophloeum* acts as a xanthine oxidase inhibitor and reduces the serum uric acid levels in oxonate-induced mice. *Phytomedicine* 2008, 15, 940–945.
3. Lee, S.-C.; Xu, W.-X.; Lin, L.-Y.; Yang, J.-J.; Liu, C.-T. Chemical Composition and Hypoglycemic and Pancreas-Protective Effect of Leaf Essential Oil from Indigenous Cinnamon (*Cinnamomum osmophloeum* Kanehira). *J. Agric. Food Chem.* 2013, 61, 4905–4913.
4. Chao, L.K.; Chang, W.T.; Shih, Y.W.; Huang, J.S. Cinnamaldehyde impairs high glucose-induced hypertrophy in renal interstitial fibroblasts. *Toxicol Appl. Pharm.* 2010, 244, 174–180.
5. Huang, J.-S.; Lee, Y.-H.; Chuang, L.-Y.; Guh, J.-Y.; Hwang, J.-Y. Cinnamaldehyde and Nitric Oxide Attenuate Advanced Glycation End Products-Induced the JAK/STAT Signaling in Human Renal Tubular Cells. *J. Cell. Biochem.* 2015, 116, 1028–1038.
6. Tung, Y.-T.; Huang, C.-C.; Ho, S.-T.; Kuo, Y.-H.; Lin, C.-C.; Lin, C.-T.; Wu, J.-H. Bioactive Phytochemicals of Leaf Essential Oils of *Cinnamomum osmophloeum* Prevent Lipopolysaccharide/d-Galactosamine (LPS/d-GalN)-Induced Acute Hepatitis in Mice. *J. Agric. Food Chem.* 2011, 59, 8117–8123.

7. Yang, L.; Wu, Q.-Q.; Liu, Y.; Hu, Z.-F.; Bian, Z.-Y.; Tang, Q.-Z. Cinnamaldehyde attenuates pressure overload-induced cardiac hypertrophy. *Int. J. Clin. Exp. Pathol.* 2015, 8, 14345–14354.
8. Raber-Durlacher, J.E.; Elad, S.; Barasch, A. Oral mucositis. *Oral Oncol.* 2010, 46, 452–456.
9. Elting, L.S.; Cooksley, C.D.; Chambers, M.S.; Garden, A.S. Risk, Outcomes, and Costs of Radiation-Induced Oral Mucositis Among Patients With Head-and-Neck Malignancies. *Int. J. Radiat. Oncol. Biol. Phys.* 2007, 68, 1110–1120.
10. Elting, L.S.; Keefe, D.M.; Sonis, S.T.; Garden, A.S.; Spijkervet, F.K.L.; Barasch, A.; Tishler, R.B.; Canty, T.P.; Kudrimoti, M.K.; Vera-Llonch, M.; et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. *Cancer* 2008, 113, 2704–2713.
11. Murphy, B.A.; Beaumont, J.L.; Isitt, J.; Garden, A.S.; Gwede, C.K.; Trotti, A.M.; Meredith, R.F.; Epstein, J.B.; Le, Q.-T.; Brizel, D.M.; et al. Mucositis-Related Morbidity and Resource Utilization in Head and Neck Cancer Patients Receiving Radiation Therapy With or Without Chemotherapy. *J. Pain Symptom Manag.* 2009, 38, 522–532.
12. Lalla, R.V.; Sonis, S.T.; Peterson, D.E. Management of oral mucositis in patients who have cancer. *Dent. Clin. North. Am.* 2008, 52, 61-viii.
13. Sonis, S.; Treister, N. Oral mucositis. In *Oral complications of cancer and its management*, 1st ed.; Davies, A., Epstein, J., Eds.; Oxford University Press: Oxford, UK; New York, NY, USA, 2010; Volume 1, pp. 141–148.
14. Sonis, S.T. Pathobiology of oral mucositis: Novel insights and opportunities. *J. Supportive Oncol.* 2007, 5, 3–11.
15. Sonis, S.T. New thoughts on the initiation of mucositis. *Oral Dis.* 2010, 16, 597–600.
16. Sonis, S.T. The pathobiology of mucositis. *Nat. Rev. Cancer* 2004, 4, 277–284.
17. Baharvand, M.; Jafari, S.; Mortazavi, H. Herbs in Oral Mucositis. *J. Clin. Diagn Res.* 2017, 11, ZE05–ZE11.
18. Ku, W.-c.; Chang, Y.-l.; Wu, S.-f.; Shih, H.-n.; Tzeng, Y.-m.; Kuo, H.-r.; Chang, K.-m.; Agrawal, D.C.; Liu, B.-l.; Chang, C.-a.; et al. A comparative proteomic study of secretomes in kaempferitrin-treated CTX TNA2 astrocytic cells. *Phytomedicine* 2017, 36, 137–144.
19. Tung, Y.-T.; Chua, M.-T.; Wang, S.-Y.; Chang, S.-T. Anti-inflammation activities of essential oil and its constituents from indigenous cinnamon (*Cinnamomum osmophloeum*) twigs. *Bioresour. Technol.* 2008, 99, 3908–3913.
20. Tung, Y.T.; Yen, P.L.; Lin, C.Y.; Chang, S.T. Anti-inflammatory activities of essential oils and their constituents from different provenances of indigenous cinnamon (*Cinnamomum osmophloeum*) leaves. *Pharm. Biol.* 2010, 48, 1130–1136.
21. Chao, L.K.; Hua, K.-F.; Hsu, H.-Y.; Cheng, S.-S.; Lin, I.F.; Chen, C.-J.; Chen, S.-T.; Chang, S.-T. Cinnamaldehyde inhibits pro-inflammatory cytokines secretion from monocytes/macrophages through suppression of intracellular signaling. *Food Chem. Toxicol.* 2008, 46, 220–231.
22. Fang, S.-H.; Rao, Y.K.; Tzeng, Y.-M. Inhibitory effects of flavonol glycosides from *Cinnamomum osmophloeum* on inflammatory mediators in LPS/IFN- γ -activated murine macrophages. *Bioorganic Med. Chem.* 2005, 13, 2381–2388.
23. Lin, H.-Y.; Chang, S.-T. Kaempferol glycosides from the twigs of *Cinnamomum osmophloeum* and their nitric oxide production inhibitory activities. *Carbohydr. Res.* 2012, 364, 49–53.
24. Lee, S.-C.; Wang, S.-Y.; Li, C.-C.; Liu, C.-T. Anti-inflammatory effect of cinnamaldehyde and linalool from the leaf essential oil of *Cinnamomum osmophloeum* Kanehira in endotoxin-induced mice. *J. Food Drug Anal.* 2018, 26, 211–220.
25. Chao, L.K.; Hua, K.-F.; Hsu, H.-Y.; Cheng, S.-S.; Liu, J.-Y.; Chang, S.-T. Study on the Antiinflammatory Activity of Essential Oil from Leaves of *Cinnamomum osmophloeum*. *J. Agric. Food Chem.* 2005, 53, 7274–7278.
26. Chang, S.-T.; Chen, P.-F.; Chang, S.-C. Antibacterial activity of leaf essential oils and their constituents from *Cinnamomum osmophloeum*. *J. Ethnopharmacol.* 2001, 77, 123–127.
27. Chang, C.W.; Chang, W.L.; Chang, S.T.; Cheng, S.S. Antibacterial activities of plant essential oils against *Legionella pneumophila*. *Water Res.* 2008, 42, 278–286.
28. Cheng, S.-S.; Liu, J.-Y.; Hsui, Y.-R.; Chang, S.-T. Chemical polymorphism and antifungal activity of essential oils from leaves of different provenances of indigenous cinnamon (*Cinnamomum osmophloeum*). *Bioresour. Technol.* 2006, 97, 306–312.
29. Wang, S.-Y.; Chen, P.-F.; Chang, S.-T. Antifungal activities of essential oils and their constituents from indigenous cinnamon (*Cinnamomum osmophloeum*) leaves against wood decay fungi. *Bioresour. Technol.* 2005, 96, 813–818.
30. Chua, M.T.; Tung, Y.T.; Chang, S.T. Antioxidant activities of ethanolic extracts from the twigs of *Cinnamomum osmophloeum*. *Bioresour Technol* 2008, 99, 1918–1925.

31. Yu, C.-W.; Li, W.-H.; Hsu, F.-L.; Yen, P.-L.; Chang, S.-T.; Liao, V.H.-C. Essential Oil Alloaromadendrene from Mixed-Type *Cinnamomum osmophloeum* Leaves Prolongs the Lifespan in *Caenorhabditis elegans*. *J. Agric. Food Chem.* 2014, 62, 6159–6165.
32. Yeh, H.-F.; Luo, C.-Y.; Lin, C.-Y.; Cheng, S.-S.; Hsu, Y.-R.; Chang, S.-T. Methods for Thermal Stability Enhancement of Leaf Essential Oils and Their Main Constituents from Indigenous Cinnamon (*Cinnamomum osmophloeum*). *J. Agric. Food Chem.* 2013, 61, 6293–6298.
33. Hsu, F.-L.; Li, W.-H.; Yu, C.-W.; Hsieh, Y.-C.; Yang, Y.-F.; Liu, J.-T.; Shih, J.; Chu, Y.-J.; Yen, P.-L.; Chang, S.-T.; et al. In Vivo Antioxidant Activities of Essential Oils and Their Constituents from Leaves of the Taiwanese *Cinnamomum osmophloeum*. *J. Agric. Food Chem.* 2012, 60, 3092–3097.
34. Lin, T.-Y.; Liao, J.-W.; Chang, S.-T.; Wang, S.-Y. Antidyslipidemic Activity of Hot-water Extracts from Leaves of *Cinnamomum osmophloeum* Kaneh. *Phytother. Res.* 2011, 25, 1317–1322.
35. Lin, G.M.; Chen, Y.H.; Yen, P.L.; Chang, S.T. Antihyperglycemic and antioxidant activities of twig extract from *Cinnamomum osmophloeum*. *J. Tradit Complement. Med.* 2016, 6, 281–288.
36. Chen, T.H.; Huang, Y.H.; Lin, J.J.; Liao, B.C.; Wang, S.Y.; Wu, Y.C.; Jong, T.T. Cytotoxic lignan esters from *Cinnamomum osmophloeum*. *Planta Med.* 2010, 76, 613–619.
37. Lee, M.-J.; Rao, Y.K.; Chen, K.; Lee, Y.-C.; Tzeng, Y.-M. Effect of flavonol glycosides from *cinnamomum osmophloeum* leaves on adiponectin secretion and phosphorylation of insulin receptor- β in 3T3-L1 adipocytes. *J. Ethnopharmacol.* 2009, 126, 79–85.
38. Cheng, B.-H.; Sheen, L.-Y.; Chang, S.-T. Evaluation of anxiolytic potency of essential oil and s-(+)-linalool from *cinnamomum osmophloeum* ct. Linalool leaves in mice. *J. Tradit. Complement Med.* 2014, 5, 27–34.
39. Lee, M.-G.; Kuo, S.-Y.; Yen, S.-Y.; Hsu, H.-F.; Leung, C.-H.; Ma, D.-L.; Wen, Z.-H.; Wang, H.-M.D. Evaluation of *Cinnamomum osmophloeum* Kanehira Extracts on Tyrosinase Suppressor, Wound Repair Promoter, and Antioxidant. *Sci. World J.* 2015, 2015, 7.
40. Rao, Y.K.; Fang, S.-H.; Tzeng, Y.-M. Evaluation of the anti-inflammatory and anti-proliferation tumoral cells activities of *Antrodia camphorata*, *Cordyceps sinensis*, and *Cinnamomum osmophloeum* bark extracts. *J. Ethnopharmacol.* 2007, 114, 78–85.
41. Cheng, B.H.; Sheen, L.Y.; Chang, S.T. Hypolipidemic effects of S-(+)-linalool and essential oil from *Cinnamomum osmophloeum* ct. linalool leaves in mice. *J. Tradit Complement. Med.* 2018, 8, 46–52.
42. Lin, S.-S.C.; Lu, T.-M.; Chao, P.-C.; Lai, Y.-Y.; Tsai, H.-T.; Chen, C.-S.; Lee, Y.-P.; Chen, S.-C.; Chou, M.-C.; Yang, C.-C. In Vivo Cytokine Modulatory Effects of Cinnamaldehyde, the Major Constituent of Leaf Essential Oil from *Cinnamomum osmophloeum* Kaneh. *Phytother. Res.* 2011, 25, 1511–1518.
43. Lee, S.-C.; Hsu, J.-S.; Li, C.-C.; Chen, K.-M.; Liu, C.-T. Protective Effect of Leaf Essential Oil from *Cinnamomum osmophloeum* Kanehira on Endotoxin-Induced Intestinal Injury in Mice Associated with Suppressed Local Expression of Molecules in the Signaling Pathways of TLR4 and NLRP3. *PLoS ONE* 2015, 10, e0120700.
44. Theurer, M.; Shaik, N.; Lang, F. Stimulation of suicidal erythrocyte death by trans-cinnamaldehyde. *Phytomedicine* 2013, 20, 1119–1123.
45. Huang, C.-Y.; Yeh, T.-F.; Hsu, F.-L.; Lin, C.-Y.; Chang, S.-T.; Chang, H.-T. Xanthine Oxidase Inhibitory Activity and Thermostability of Cinnamaldehyde-Chemotype Leaf Oil of *Cinnamomum osmophloeum* Microencapsulated with β -Cyclodextrin. *Molecules* 2018, 23, 1107.
46. Lin, G.-M.; Lin, H.-Y.; Hsu, C.-Y.; Chang, S.-T. Structural characterization and bioactivity of proanthocyanidins from indigenous cinnamon (*Cinnamomum osmophloeum*). *J. Sci. Food Agric.* 2016, 96, 4749–4759.
47. Curra, M.; Soares Junior, L.A.V.; Martins, M.D.; Santos, P.S.d.S. Chemotherapy protocols and incidence of oral mucositis. An integrative review. *Einstein (Sao Paulo)* 2018, 16, eRW4007.
48. Köstler, W.J.; Hejna, M.; Wenzel, C.; Zielinski, C.C. Oral Mucositis Complicating Chemotherapy and/or Radiotherapy: Options for Prevention and Treatment. *CA: A Cancer J. Clin.* 2001, 51, 290–315.
49. Lalla, R.V.; Bowen, J.; Barasch, A.; Elting, L.; Epstein, J.; Keefe, D.M.; McGuire, D.B.; Migliorati, C.; Nicolatou-Galitis, O.; Peterson, D.E.; et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. *Cancer* 2014, 120, 1453–1461.
50. Molania, T.; Moghadamnia, A.A.; Pouramir, M.; Aghel, S.; Moslemi, D.; Ghassemi, L.; Motallebnejad, M. The effect of Cinnamaldehyde on mucositis and salivary antioxidant capacity in gamma-irradiated rats (a preliminary study). *Daru* 2012, 20, 89.

51. Parkins, C.S.; Fowler, J.F.; Yu, S. A murine model of lip epidermal/mucosal reactions to X-irradiation. *Radiother. Oncol.* 1983, 1, 159–165.
52. Veilleux, M.-P.; Grenier, D. Determination of the effects of cinnamon bark fractions on *Candida albicans* and oral epithelial cells. *BMC Complement. Altern. Med.* 2019, 19, 303.
53. Feghali, K.; Feldman, M.; La, V.D.; Santos, J.; Grenier, D. Cranberry Proanthocyanidins: Natural Weapons against Periodontal Diseases. *J. Agric. Food Chem.* 2012, 60, 5728–5735.
54. Raeessi, M.A.; Raeessi, N.; Panahi, Y.; Gharaie, H.; Davoudi, S.M.; Saadat, A.; Karimi Zarchi, A.A.; Raeessi, F.; Ahmadi, S.M.; Jalalian, H. "Coffee plus honey" versus "topical steroid" in the treatment of chemotherapy-induced oral mucositis: A randomised controlled trial. *BMC Complement. Altern. Med.* 2014, 14, 293.
55. Fidler, P.; Loprinzi, C.L.; O'Fallon, J.R.; Leitch, J.M.; Lee, J.K.; Hayes, D.L.; Novotny, P.; Clemens-Schutjer, D.; Bartel, J.; Michalak, J.C. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. *Cancer* 1996, 77, 522–525.
56. Mazokopakis, E.E.; Vrentzos, G.E.; Papadakis, J.A.; Babalis, D.E.; Ganotakis, E.S. Wild chamomile (*Matricaria recutita* L.) mouthwashes in methotrexate-induced oral mucositis. *Phytomedicine* 2005, 12, 25–27.
57. Pourdeghatkar, F.; Motaghi, M.; Darbandi, B.; BagherSalimi, A. The Effect of Chamomile Mouthwash on the Prevention of Oral Mucositis Caused by Chemotherapy in Children with Acute Lymphoblastic Leukemia. *SSU* 2017, 7, 76–81.
58. Aoyama, T.; Nishikawa, K.; Takiguchi, N.; Tanabe, K.; Imano, M.; Fukushima, R.; Sakamoto, J.; Oba, M.S.; Morita, S.; Kono, T.; et al. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. *Cancer Chemother Pharm.* 2014, 73, 1047–1054.
59. Kono, T.; Kaneko, A.; Matsumoto, C.; Miyagi, C.; Ohbuchi, K.; Mizuhara, Y.; Miyano, K.; Uezono, Y. Multitargeted Effects of Hangeshashinto for Treatment of Chemotherapy-Induced Oral Mucositis on Inducible Prostaglandin E2 Production in Human Oral Keratinocytes. *Integr. Cancer Ther.* 2014, 13, 435–445.
60. You, W.C.; Hsieh, C.C.; Huang, J.T. Effect of Extracts from Indigowood Root (*Isatis indigotica* Fort.) on Immune Responses in Radiation-Induced Mucositis. *J. Altern. Complementary Med.* 2009, 15, 771–778.
61. Tiemann, P.; Toelg, M.; Ramos, F.M.H. Administration of Ratanhia-based herbal oral care products for the prophylaxis of oral mucositis in cancer chemotherapy patients: A clinical trial. *Evid Based Complement. Altern. Med.* 2007, 4, 361–366.
62. Sahebamee, M.; Mansourian, A.; Hajimirzamohammad, M.; Zadeh, M.T.; Bekhradi, R.; Kazemian, A.; Manifar, S.; Ashnagar, S.; Doroudgar, K. Comparative Efficacy of Aloe vera and Benzydamine Mouthwashes on Radiation-induced Oral Mucositis: A Triple-blind, Randomised, Controlled Clinical Trial. *Oral Health Prev. Dent.* 2015, 13, 309–315.
63. Hawley, P.; Hovan, A.; McGahan, C.E.; Saunders, D. A randomized placebo-controlled trial of manuka honey for radiation-induced oral mucositis. *Supportive Care Cancer* 2014, 22, 751–761.
64. Miranzadeh, S.; Adib-Hajbaghery, M.; Soleymanpoor, L.; Ehsani, M. A New mouthwash for Chemotherapy Induced Stomatitis. *Nurs. Midwifery Stud.* 2014, 3, e20249.
65. Babaei, N.; Moslemi, D.; Khalilpour, M.; Vejdani, F.; Moghadamnia, Y.; Bijani, A.; Baradaran, M.; Kazemi, M.T.; Khalilpour, A.; Pouramir, M.; et al. Antioxidant capacity of calendula officinalis flowers extract and prevention of radiation induced oropharyngeal mucositis in patients with head and neck cancers: A randomized controlled clinical study. *Daru* 2013, 21, 18.
66. Khanal, B.; Baliga, M.; Uppal, N. Effect of topical honey on limitation of radiation-induced oral mucositis: An intervention study. *Int. J. Oral Maxillofac. Surg.* 2010, 39, 1181–1185.
67. Kuduban, O.; Mazlumoglu, M.R.; Kuduban, S.D.; Erhan, E.; Cetin, N.; Kukula, O.; Yarali, O.; Cimen, F.K.; Cankaya, M. The effect of hippophae rhamnoides extract on oral mucositis induced in rats with methotrexate. *J. Appl Oral Sci* 2016, 24, 423–430.
68. Motallebnejad, M.; Akram, S.; Moghadamnia, A.; Moulana, Z.; Omid, S. The effect of topical application of pure honey on radiation-induced mucositis: A randomized clinical trial. *J. Contemp. Dent. Pract.* 2008, 9, 40–47.
69. Rashad, U.M.; Al-Gezawy, S.M.; El-Gezawy, E.; Azzaz, A.N. Honey as topical prophylaxis against radiochemotherapy-induced mucositis in head and neck cancer. *J. Laryngol. Otol.* 2009, 123, 223–228.
70. Lambros, M.P.; Kondapalli, L.; Parsa, C.; Mulamalla, H.C.; Orlando, R.; Pon, D.; Huang, Y.; Chow, M.S.S. Molecular signatures in the prevention of radiation damage by the synergistic effect of n-acetyl cysteine and qingre liyan decoction, a traditional chinese medicine, using a 3-dimensional cell culture model of oral mucositis. *Evid. Based Complement Alternat. Med.* 2015, 2015, 425760.

71. Loo, W.T.Y.; Jin, L.J.; Chow, L.W.C.; Cheung, M.N.B.; Wang, M. Rhodiola algida improves chemotherapy-induced oral mucositis in breast cancer patients. *Expert Opin. Investig. Drugs* 2010, 19, S91–S100.
72. Wu, M.-h.; Yuan, B.; Liu, Q.-f.; Wang, Q. Study of qingre liyan decoction (清热利咽汤) in treating and preventing acute radioactive oral mucositis. *Chin. J. Integr. Med.* 2007, 13, 280–284.
73. Puataweepong, P.; Dhanachai, M.; Dangprasert, S.; Sithatani, C.; Sawangsilp, T.; Narkwong, L.; Puttikaran, P.; Intragumtornchai, T. The efficacy of oral aloe vera juice for radiation induced mucositis in head and neck cancer patients: A double-blind placebo-controlled study. *Asian Biomedicine* 2009, 3, 375–382.
74. De Freitas Cuba, L.; Braga Filho, A.; Cherubini, K.; Salum, F.G.; Figueiredo, M.A.Z.d. Topical application of aloe vera and vitamin e on induced ulcers on the tongue of rats subjected to radiation: Clinical and histological evaluation. *Support. Care Cancer* 2016, 24, 2557–2564.
75. Sencer, S.F.; Zhou, T.; Freedman, L.S.; Ives, J.A.; Chen, Z.; Wall, D.; Nieder, M.L.; Grupp, S.A.; Yu, L.C.; Sahdev, I.; et al. Traumeel s in preventing and treating mucositis in young patients undergoing sct: A report of the children's oncology group. *Bone Marrow Transplant* 2012, 47, 1409–1414.
76. Braga, F.T.M.M.; Santos, A.C.F.; Bueno, P.C.P.; Silveira, R.C.C.P.; Santos, C.B.; Bastos, J.K.; Carvalho, E.C. Use of chamomilla recutita in the prevention and treatment of oral mucositis in patients undergoing hematopoietic stem cell transplantation: A randomized, controlled, phase ii clinical trial. *Cancer Nursing* 2015, 38, 322–329.
77. Napeñas, J.J.; Brennan, M.T.; Coleman, S.; Kent, M.L.; Noll, J.; Frenette, G.; Nussbaum, M.L.; Mougeot, J.-L.; Paster, B.J.; Lockhart, P.B.; et al. Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: A pilot study. *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol.* 2010, 109, 554–560.
78. Sonalika, W.G.; Amsavardani Tayaar, S.; Bhat, K.G.; Patil, B.R.; Muddapur, M.V. Oral microbial carriage in oral squamous cell carcinoma patients at the time of diagnosis and during radiotherapy – A comparative study. *Oral Oncol.* 2012, 48, 881–886.
79. Panghal, M.; Kaushal, V.; Kadayan, S.; Yadav, J.P. Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocols. *BMC Oral Health* 2012, 12, 22.
80. Laheij, A.M.G.A.; de Soet, J.J.; von dem Borne, P.A.; Kuijper, E.J.; Kraneveld, E.A.; van Loveren, C.; Raber-Durlacher, J.E. Oral bacteria and yeasts in relationship to oral ulcerations in hematopoietic stem cell transplant recipients. *Supportive Care Cancer* 2012, 20, 3231–3240.
81. Cechinel-Zanchett, C.C.; Boeing, T.; Somensi, L.B.; Steimbach, V.M.B.; Campos, A.; Krueger, C.d.M.A.; Schultz, C.; Sant'ana, D.d.M.G.; Cechinel-Filho, V.; Mota da Silva, L.; et al. Flavonoid-rich fraction of Bauhinia forficata Link leaves prevents the intestinal toxic effects of irinotecan chemotherapy in IEC-6 cells and in mice. *Phytother. Res.* 2019, 33, 90–106.
82. Liu, Z.; Xi, J.; Schröder, S.; Wang, W.; Xie, T.; Wang, Z.; Bao, S.; Fei, J. Chimonanthus nitens var. salicifolius Aqueous Extract Protects against 5-Fluorouracil Induced Gastrointestinal Mucositis in a Mouse Model. *Evid. -Based Complementary Altern. Med.* 2013, 2013, 12.
83. Vladimir, R.A.S.N.; Gustavo, S.A.; Rafael, T.G.; Samara, H.I.; Maralice, C.B.; Evandro, N.A.; Efigenia Ferreira e, F.; Ana Cristina Viana, C.; Alexandre, A.S.; Sheila, R.L.A.; et al. Mucoadhesive Propolis Gel for Prevention of Radiation-Induced Oral Mucositis. *Curr. Clin. Pharmacol.* 2014, 9, 359–364.
84. Georgakopoulou, E.A. Cinnamon contact stomatitis. *J. Derm. Case Rep.* 2010, 4, 28–29.
85. Tremblay, S.; Avon, S.L. Contact allergy to cinnamon: Case report. *J. Can. Dent. Assoc.* 2008, 74, 445–461.
86. Calapai, G.; Miroddi, M.; Mannucci, C.; Minciullo, P.L.; Gangemi, S. Oral adverse reactions due to cinnamon-flavoured chewing gums consumption. *Oral Dis.* 2014, 20, 637–643.